Once- or twice-daily thoracic radiation in limited-stage small-cell lung cancer treated with concurrent chemoradiotherapy
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of once-daily radiotherapy versus twice-daily radiotherapy concurrently with chemotherapy for optimal survival outcomes in people with limited-stage small-cell lung cancer (LS-SCLC).
Authors
- Kazuya Inoki (ORCID: https://orcid.org/0000-0002-2703-9509)
- Ken Harada (ORCID: https://orcid.org/0000-0002-9859-6871)
- Erika Ota (ORCID: https://orcid.org/0000-0002-3945-7441)
- Kanae Taruno (ORCID: https://orcid.org/0000-0002-7754-1548)
- Takenori Ichimura (ORCID: https://orcid.org/0000-0002-4731-6032)
- Hidenori Shinjo (ORCID: https://orcid.org/0000-0001-6216-1115)
- Takeshi Hasegawa (ORCID: https://orcid.org/0000-0003-0420-5583)
- Noyuri Yamaji (ORCID: https://orcid.org/0000-0002-4212-6723)
- Hisashi Noma
Institutions
- SHOWA Medical University (JP)
- Tokyo University of Pharmacy and Life Sciences (JP)
- Tohoku University (JP)
- St. Luke's International University (JP)
- University of Tokyo Health Sciences (JP)
- The Institute of Statistical Mathematics (JP)
- SHOWA Medical University Hospital (JP)
Publication Details
- Journal
- Cochrane Database of Systematic Reviews
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1002/14651858.cd016084
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00